Stevanato Group (NYSE:STVN) announced today that it signed an exclusive agreement with Owen Mumford for its auto-injector technology. Piombino Dese, Italy-based Stevanato Group’s agreement makes it an exclusive manufacturing partner for Owen Mumford’s Aidaptus auto-injector. Under the agreement, Stevanato Group will mold the components for the technology and provide final and sub-assembly equipment, along with […]
Stevanato Group
Stevanato Group, Bexson expand partnership for wearable drug delivery device
Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration. Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and […]
Stevanato Group acquires facility set to become manufacturing hub in China
Stevanato Group (NYSE:STVN) announced today that it acquired a facility in Zhangjiagang, China, for a new manufacturing plant. Piombino Dese, Italy-based Stevanato Group expects to begin renovations on the facility in the spring of 2022 as it works to expand in China with a new manufacturing hub for drug containment, drug delivery and diagnostic development. […]
Stevanato Group extends licensing agreement with Haselmeier for pen injector tech
Stevanato Group (NYSE:STVN) announced today that it signed an extension to a licensing agreement with Haselmeier over its pen injector technology. Piombino Dese, Italy-based Stevanato Group’s license extension gives the company exclusivity to offer the Axis-D pen injector technology in support of a broader range of drugs for its biopharma customers beyond diabetes, including areas […]
FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump
Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy. Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group. According to a news release, having reached the milestone of pre-IND guidance, […]
Stevanato Group expands corporate headquarters
Stevanato Group (NYSE:STVN) announced today that it expanded its corporate headquarters with a new facility in Italy. Based in Piombino Dese, Italy, Stevanato Group said the 6,750-square-meter facility will support the optimization of its industrial footprint while advancing operations and growth within the company. About 2,500 square meters of the facility will be dedicated to […]
Stevanato Group beats The Street in Q3, raises guidance
Stevanato Group (NYSE:STVN) shares hit a snag today despite third-quarter results that beat the consensus forecast. The Piombino Dese, Italy-based drug delivery technology developer posted profits of $21.6 million, or 8¢ per share, on sales of $248.6 million for the three months ended Sept. 30, 2021, for a 12.5% bottom-line gain on sales growth of […]
Stevanato Group is constructing a new facility in Indiana
Stevanato Group (NYSE:STVN) announced today that it will begin construction on a new U.S. facility in Fishers, Indiana. Piombino Dese, Italy-based Stevanato Group will begin construction on the new facility this month with expectations for the site to be operational in 2023. According to a news release, constructing the new facility falls in line with […]
Stevanato Group brings in upsized IPO worth $453.5M
Stevanato Group announced today that the underwriters of its recently completed initial public offering purchased more than 1 million additional shares. The option exercised by the underwriters saw the acquisition of an additional 1,018,280 ordinary Stevanato Group shares at $21 per share. Piombino Dese, Italy–based Stevanato Group’s IPO resulted in net proceeds of approximately $453.5 […]
Bexson Biomedical wins U.S. patent for ketamine formulation
Bexson Biomedical announced that the U.S. Patent and Trademark Office (USPTO) granted a patent for its BB106 ketamine therapy. Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the […]
